Log in

NASDAQ:SUPN - Supernus Pharmaceuticals Stock Price, Forecast & News

$17.16
+1.09 (+6.78 %)
(As of 03/31/2020 03:38 AM ET)
Today's Range
$16.17
Now: $17.16
$17.30
50-Day Range
$14.45
MA: $19.21
$24.36
52-Week Range
$13.12
Now: $17.16
$39.15
Volume520,224 shs
Average Volume618,364 shs
Market Capitalization$901.48 million
P/E Ratio8.13
Dividend YieldN/A
Beta1.68
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company's product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Read More
Supernus Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:SUPN
CUSIP86845910
Phone301-838-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$392.76 million
Cash Flow$2.67 per share
Book Value$11.35 per share

Profitability

Net Income$113.06 million

Miscellaneous

Employees448
Market Cap$901.48 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive SUPN News and Ratings via Email

Sign-up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.


Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions

How has Supernus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Supernus Pharmaceuticals' stock was trading at $16.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SUPN shares have increased by 6.3% and is now trading at $17.16. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Supernus Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Supernus Pharmaceuticals.

When is Supernus Pharmaceuticals' next earnings date?

Supernus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Supernus Pharmaceuticals.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) issued its quarterly earnings data on Tuesday, February, 25th. The specialty pharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.57 by $0.05. The specialty pharmaceutical company earned $100.45 million during the quarter, compared to the consensus estimate of $107.27 million. Supernus Pharmaceuticals had a net margin of 28.78% and a return on equity of 20.98%. View Supernus Pharmaceuticals' earnings history.

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?

Supernus Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $360-390 million, compared to the consensus revenue estimate of $407.73 million.

What price target have analysts set for SUPN?

6 brokerages have issued 1-year price objectives for Supernus Pharmaceuticals' shares. Their forecasts range from $23.00 to $63.00. On average, they anticipate Supernus Pharmaceuticals' share price to reach $43.80 in the next twelve months. This suggests a possible upside of 155.2% from the stock's current price. View analysts' price targets for Supernus Pharmaceuticals.

What are Wall Street analysts saying about Supernus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (3/3/2020)
  • 2. Mizuho analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are adjusting our price target to $18 from $3, based on the following factors: (1) adjustment to base year; (2) adjustment ot fully diluted share count; (3) accounting for the 1 for 15 reverse split; and (4) increasing our discount rate to 30% from our usual 15%, to account for increased perceived risk in developing drugs for both pancreatic cancer and AML. We note that there is still a relatively large delta between the current share price and our target, which is now also largely attributable to the low number of shares outstanding post-reverse split." (8/7/2019)

Has Supernus Pharmaceuticals been receiving favorable news coverage?

Press coverage about SUPN stock has been trending somewhat negative on Tuesday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Supernus Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutSupernus Pharmaceuticals.

Are investors shorting Supernus Pharmaceuticals?

Supernus Pharmaceuticals saw a decline in short interest in March. As of March 13th, there was short interest totaling 5,581,700 shares, a decline of 10.4% from the February 27th total of 6,230,000 shares. Based on an average daily volume of 653,000 shares, the days-to-cover ratio is presently 8.5 days. Currently, 11.0% of the shares of the stock are sold short. View Supernus Pharmaceuticals' Current Options Chain.

Who are some of Supernus Pharmaceuticals' key competitors?

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), AbbVie (ABBV), GW Pharmaceuticals PLC- (GWPH), Exelixis (EXEL), Netflix (NFLX), Cara Therapeutics (CARA), Corcept Therapeutics (CORT) and Pfizer (PFE).

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the following people:
  • Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 58)
  • Mr. Gregory S. Patrick, Sr. VP & CFO (Age 68)
  • Dr. Padmanabh P. Bhatt, Chief Scientific Officer & Sr. VP of Intellectual Property (Age 62)
  • Dr. Stefan K. F. Schwabe, Chief Medical Officer and Exec. VP of R&D (Age 67)
  • Dr. Todd Horich M.B.A., Ph.D., VP of Marketing

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $17.16.

How big of a company is Supernus Pharmaceuticals?

Supernus Pharmaceuticals has a market capitalization of $901.48 million and generates $392.76 million in revenue each year. The specialty pharmaceutical company earns $113.06 million in net income (profit) each year or $2.10 on an earnings per share basis. Supernus Pharmaceuticals employs 448 workers across the globe. View additional information about Supernus Pharmaceuticals.

What is Supernus Pharmaceuticals' official website?

The official website for Supernus Pharmaceuticals is http://www.supernus.com/.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]


MarketBeat Community Rating for Supernus Pharmaceuticals (NASDAQ SUPN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  435 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  703
MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe SUPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SUPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Featured Article: What are retained earnings?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel